New issue
Have a question about this project? Sign up for a free GitHub account to open an issue and contact its maintainers and the community.
By clicking “Sign up for GitHub”, you agree to our terms of service and privacy statement. We’ll occasionally send you account related emails.
Already on GitHub? Sign in to your account
separate ABL1 gene/protein from BCR/ABL translocation #1
Comments
The On a related note, after reviewing this entry I noticed Drugbank actually has BRC as the pharmacological target of imantinib. ABL is also listed as a target, but pharmacologic action is listed as "Unknown." |
In the
imatinib
-CML (ph+)
path, BCR/ABL is referenced as the intermediate node in L20, with the edgesimatinib
INHIBITS
BCR/ABL
, andBCR/ABL
CAUSES
CML (ph+)
. I think this is suboptimal for two reasons.BCR/ABL
references https://www.uniprot.org/uniprot/P00519, which only describes the ABL1 protein.imatinib
INHIBITS
ABL1
HAS_VARIANT
BCR/ABL
CAUSES
CML (ph+)
. But having said that, I'm not sure there are any standard identifiers for referencing translocations and/or fusion proteins.The text was updated successfully, but these errors were encountered: